Cancer drug licensed by GSK from China posts promising trial results
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
Quarterly proceeds from Keytruda top $8bn for first time
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022
Blenrep had been removed from sale after a trial failed to show it was superior to other treatments
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda
